Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Soosay Raj, Trisha A., Smith, Amanda M. and Moore, Andrew S. (2013) Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. International Journal of Nanomedicine, 8 1: 4361-4369. doi:10.2147/IJN.S54657

Author Soosay Raj, Trisha A.
Smith, Amanda M.
Moore, Andrew S.
Title Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
Journal name International Journal of Nanomedicine   Check publisher's open access policy
ISSN 1178-2013
Publication date 2013-11-06
Sub-type Critical review of research, literature review, critical commentary
DOI 10.2147/IJN.S54657
Open Access Status DOI
Volume 8
Issue 1
Start page 4361
End page 4369
Total pages 9
Place of publication Winterton Way, Macclesfield, United Kingdom
Publisher Dove Medical Press
Language eng
Subject 1304 Biophysics
1502 Banking, Finance and Investment
2502 Biomaterials
1605 Policy and Administration
3002 Drug Discovery
Formatted abstract
Vincristine (VCR) is one of the most extensively used cytotoxic compounds in hemato-oncology. VCR is particularly important for the treatment of acute lymphoblastic leukemia (ALL), a disease that accounts for approximately one-third of all childhood cancer diagnoses. VCR's full therapeutic potential has been limited by dose-limiting neurotoxicity, classically resulting in autonomic and peripheral sensory–motor neuropathy. In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies. Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR–ABL1) (Ph)-negative (Ph-) disease. Additional clinical trials of VSLI in adults and children with both Ph-positive (Ph+) and Ph- ALL are ongoing. Here we review the preclinical and clinical experience to date with VSLI for ALL.
Keyword Acute lymphoblastic leukemia
Sphingosomal vincristine
Vincristine sulfate liposomal injection
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Faculty of Health and Behavioural Sciences -- Publications
Official 2014 Collection
Queensland Children's Medical Research Institute Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 11 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 03 Dec 2013, 10:47:03 EST by System User on behalf of Child Health Research Centre